
Eyepoint Pharmaceuticals (NASDAQ:EYPT) is focusing on diabetic macular edema after its treatment DURAVYU missed the primary endpoint in two late-stage trials for wet age-related macular degeneration, CEO Jay Duker said.
The company’s two Phase 3 diabetic macular edema, or DME, trials, COMO and CAPRI, are fully enrolled. Duker said top-line results are expected in early fourth quarter of the year following the discussion. The transcript did not specify the date of the event.
Duker described EyePoint as “a DME company” and estimated the worldwide market for the condition at $5 billion, including $3 billion in the U.S.
Wet AMD Results and DME Outlook
DURAVYU failed to demonstrate non-inferiority to EYLEA on the primary vision endpoint in the LUGANO and LUCIA wet AMD trials. Duker said the drug showed activity, with patients gaining more than two letters of visual acuity in both trials, but “wasn’t able to hold the vision quite enough to be non-inferior.”
He said more than half of treated eyes in each trial needed no supplemental treatment after the initial loading period through week 56. EyePoint is analyzing biomarkers and patient characteristics to see whether it can identify in advance those who respond well or poorly, but Duker said the company has not found a definitive factor.
Duker also pointed to safety, retinal fluid control and reduced treatment burden in the wet AMD trials as reasons for optimism about DME. He said treated patients received an average of about two fewer injections than patients receiving EYLEA on its labeled schedule. Those findings do not establish that DURAVYU will succeed in DME.
Duker said the diseases differ: wet AMD primarily involves new blood vessel growth and is largely VEGF-mediated, while DME involves leaking retinal blood vessels and both VEGF and inflammatory factors. He cited corticosteroids as an example of treatments that work well in DME but have virtually no effect in wet AMD.
In EyePoint’s Phase 2 VERONA DME trial, Duker said the 2.7-milligram DURAVYU dose produced the same visual acuity as EYLEA at 24 weeks, with fewer rescue treatments and less retinal fluid. He said an observed reduction in leakage suggested a possible anti-inflammatory effect, but cautioned that the company could not establish the mechanism with certainty.
Duker also said EyePoint has never tested DURAVYU without at least one dose of EYLEA, so it does not know whether an anti-VEGF treatment is needed alongside it.
Trial Changes and Cash Runway
EyePoint has changed the rescue criteria in its DME trials to a five-letter decline in vision and 50 microns of fluid from a patient’s best result during the study, from a previous threshold of 10 letters and 50 microns, Duker said. He said the change should affect few patients. The company had not held formal FDA discussions about significant protocol changes, he added.
CFO George Elston said EyePoint reduced its workforce by about 53% following the LUCIA result and ended September with approximately $118 million in cash. The company is working through scenarios intended to get its cash to and hopefully through the DME data readout, without assuming financing or a partnership.
The workforce reduction is expected to yield about $30 million in annualized savings, although Elston said those savings would not begin to materialize until around the middle of the following year because of severance and related costs. EyePoint has also extended part of the second year of its wet AMD trials to help obtain safety data from 300 patients for a potential DME application, he said.
About Eyepoint Pharmaceuticals (NASDAQ:EYPT)
EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.
